Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995906344> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2995906344 endingPage "1893" @default.
- W2995906344 startingPage "1887" @default.
- W2995906344 abstract "To evaluate the efficacy and safety of carfilzomib in the treatment of multiple myeloma (MM).Computer was used to search PubMed, EMbase, Cochrane library and MEDLINE databases for carfilzomib treatment of MM. Clinical features and results were extracted and meta-analysis was performed using Stata12.0 software.Twelve eligible Phase I/II, II and III clinical trials of carfilzomib were extracted and 2 487 MM patients involved in evaluable. The summary analysis showed that the rate of complete response (CR) of carfilzomib treatment was 28%, the rate of ≥very good partial response (VGPR) was 73%, and the rate of overall response rate (0RR) was 93%; the 1-year progression-free survival (PFS) rate of MM patients was 93%, the 2-year PFS rate was 85%, and the 3-year PFS rate was 74%. Three randomized controlled trials showed a significant improvement in ORR [OR=1.644, 95% CI=(1.056, 2.560) ] (P＜0.05) and clinical benefit rate (CBR) in MM patients [OR=1.595, 95%) CI=(1.044, 2.435) ] (P＜0.05). Compared with the control group, the OR of cardiotoxicity (P＜0.05) was significantly increased, while that of peripheral neuropathy (P＞0.05) was not significantly changed.Compared with traditional treatments, carfilzomib significantly improves survival in the patients with multiple myeloma without increasing the incidence of peripheral neuropathy, but the incidence of cardiotoxicity seems higher.卡非佐米治疗多发性骨髓瘤的疗效及安全性的系统评价.评估卡非佐米（Carfizomib）治疗多发性骨髓瘤（multiple myeloma，MM）的疗效及安全性.计算机检索PubMed、EMbase、Cochrane library、MEDLINE数据库关于卡非佐米治疗MM的研究，提取临床特征和结果，使用Stata 12.0软件进行Meta分析.确定12个符合条件的关于卡非佐米的Ⅰ/Ⅱ期、Ⅱ和Ⅲ期临床试验，涉及2 487名可评估的MM患者。汇总分析显示,卡非佐米治疗MM达到完全反应（≥complete response，CR）率为28%，非常好的部分反应（≥very good partial response，VGPR）率为73%,总反应率（overall response rate，0RR）为93%。MM患者1年无进展生存（progression-free survival，PFS）率为93%，2、3年PFS率分别为85%和74%。3个随机对照试验结果显示，MM患者的ORR [OR=1.644，95％CI=（1.056，2.560）] （P=0.028）及临床获益率（clinical benefit rate，CBR）[OR=1.595，95％CI=1.044和2.435]（P=0.031）均得到显著改善。与对照组相比，应用卡非佐米的患者发生心脏毒性（P=0.01）的OR显着升高，而周围神经病变（P=0.25）无明显变化.与传统治疗方法相比，卡非佐米明显改善多发性骨髓瘤患者的生存，未增加周围神经病变发生率，但心脏毒性的发病率似乎更高." @default.
- W2995906344 created "2019-12-26" @default.
- W2995906344 creator A5072090945 @default.
- W2995906344 creator A5086919636 @default.
- W2995906344 date "2019-12-01" @default.
- W2995906344 modified "2023-10-18" @default.
- W2995906344 title "[Efficacy and Safety of Carfilzomib in the Treatment of Multiple Myeloma：A Systematic Evaluation]." @default.
- W2995906344 doi "https://doi.org/10.19746/j.cnki.issn.1009-2137.2019.06.029" @default.
- W2995906344 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31839055" @default.
- W2995906344 hasPublicationYear "2019" @default.
- W2995906344 type Work @default.
- W2995906344 sameAs 2995906344 @default.
- W2995906344 citedByCount "0" @default.
- W2995906344 crossrefType "journal-article" @default.
- W2995906344 hasAuthorship W2995906344A5072090945 @default.
- W2995906344 hasAuthorship W2995906344A5086919636 @default.
- W2995906344 hasConcept C120665830 @default.
- W2995906344 hasConcept C121332964 @default.
- W2995906344 hasConcept C126322002 @default.
- W2995906344 hasConcept C143998085 @default.
- W2995906344 hasConcept C168563851 @default.
- W2995906344 hasConcept C17744445 @default.
- W2995906344 hasConcept C199539241 @default.
- W2995906344 hasConcept C2776364478 @default.
- W2995906344 hasConcept C2776478404 @default.
- W2995906344 hasConcept C2776694085 @default.
- W2995906344 hasConcept C2777478702 @default.
- W2995906344 hasConcept C2778233292 @default.
- W2995906344 hasConcept C2779473830 @default.
- W2995906344 hasConcept C2780108899 @default.
- W2995906344 hasConcept C535046627 @default.
- W2995906344 hasConcept C61511704 @default.
- W2995906344 hasConcept C71924100 @default.
- W2995906344 hasConcept C95190672 @default.
- W2995906344 hasConceptScore W2995906344C120665830 @default.
- W2995906344 hasConceptScore W2995906344C121332964 @default.
- W2995906344 hasConceptScore W2995906344C126322002 @default.
- W2995906344 hasConceptScore W2995906344C143998085 @default.
- W2995906344 hasConceptScore W2995906344C168563851 @default.
- W2995906344 hasConceptScore W2995906344C17744445 @default.
- W2995906344 hasConceptScore W2995906344C199539241 @default.
- W2995906344 hasConceptScore W2995906344C2776364478 @default.
- W2995906344 hasConceptScore W2995906344C2776478404 @default.
- W2995906344 hasConceptScore W2995906344C2776694085 @default.
- W2995906344 hasConceptScore W2995906344C2777478702 @default.
- W2995906344 hasConceptScore W2995906344C2778233292 @default.
- W2995906344 hasConceptScore W2995906344C2779473830 @default.
- W2995906344 hasConceptScore W2995906344C2780108899 @default.
- W2995906344 hasConceptScore W2995906344C535046627 @default.
- W2995906344 hasConceptScore W2995906344C61511704 @default.
- W2995906344 hasConceptScore W2995906344C71924100 @default.
- W2995906344 hasConceptScore W2995906344C95190672 @default.
- W2995906344 hasIssue "6" @default.
- W2995906344 hasLocation W29959063441 @default.
- W2995906344 hasOpenAccess W2995906344 @default.
- W2995906344 hasPrimaryLocation W29959063441 @default.
- W2995906344 hasRelatedWork W2285623597 @default.
- W2995906344 hasRelatedWork W2599319608 @default.
- W2995906344 hasRelatedWork W2759947093 @default.
- W2995906344 hasRelatedWork W2768048615 @default.
- W2995906344 hasRelatedWork W2790231717 @default.
- W2995906344 hasRelatedWork W2793191657 @default.
- W2995906344 hasRelatedWork W2912170340 @default.
- W2995906344 hasRelatedWork W2935364901 @default.
- W2995906344 hasRelatedWork W3032559208 @default.
- W2995906344 hasRelatedWork W3213074919 @default.
- W2995906344 hasVolume "27" @default.
- W2995906344 isParatext "false" @default.
- W2995906344 isRetracted "false" @default.
- W2995906344 magId "2995906344" @default.
- W2995906344 workType "article" @default.